

CLINICAL RESEARCH NEWSLETTER - MAY 2026

Alaina Newsome; GA NCORP CCDR
 Program Coordinator; underberga@sjchs.org

SAVE THE DATE

**I&A: Administrators, Managers, Coordinators
 &
 Advanced Practice Providers Meeting**

June 5, 2026

In Person: Lewis Cancer and Research Pavilion
 225 Candler Dr. Savannah, GA 31405

Virtual: Link (will be provided after registration)
 If you are interested in attending this meeting in
 person, there are funds available!

I&A WITH GASCO

Meeting Host: Georgia Society of Clinical
 Oncology

August 20, 2026

Where: The Hotel at Avalon
 Alpharetta, GA

More Information to come

Please reach out to Shantoria Brown at sbrown@georgiacore.org for more information

STUDY SPOTLIGHT

URCC study in development

Plant-Based Lifestyle Adaptation for Nutrition Therapy in
 Patients with Metastatic Breast Cancer

A Phase II Feasibility Randomized Controlled Trial of a Remotely
 Delivered Whole-Food, Plant-Based Dietary Intervention to
 Improve Quality of Life and Reduce Symptom Burden in Women
 with Metastatic Breast Cancer.

The study includes a 26-week remotely delivered dietary
 intervention focused on whole-food, plant-based nutrition.

Participants randomized to the intervention will receive
 prepared, frozen meals, with a gradual transition to grocery
 delivery and guided recipe preparation. Group education
 sessions will also be incorporated to support adherence and
 engagement throughout the intervention.

HAPPY CLINICAL TRIALS DAY - MAY 20

Each year on May 20, we honor
 the patients, researchers, site
 staff, and advocates who make
 clinical research possible. Clinical
 trials are the foundation of
 cancer care advancement, and
 we are grateful for everyone
 across the NCORP network who
 helps bring life-changing
 research from concept to care.

Table of Contents

TOPIC	PAGE
Save the date/Study Spotlight	1
Research Base - ECOG	2
Research Base - SWOG	3
NCORP News	4
CORE Fundamentals	5
Recently Activated and Recommended Trials	6
OPEN AND ENROLLING CANCER CARE DELIVERY RESEARCH (CCDR) TRIALS ¹	7

MARK YOUR CALENDAR

May 25

Memorial Day
 Georgia CORE
 Closed

Jun 05

I&A: Administrators,
 Managers,
 Coordinators &
 Advanced Practice
 Providers Meeting

Jun 19

Juneteenth
 Georgia CORE
 Closed

July 03

Georgia CORE
 Closed for 4th of
 July Observance

CLINICAL RESEARCH NEWSLETTER - MAY 2026

Research Base News

WHAT'S NEW WITH ECOG-ACRIN

CCDR Update

CCDR portfolio has reached a record high, with 10 studies currently open and a total of 38 protocols active within the NCORP network. Over 14,000 participants have been accrued to CCDR studies to date, a milestone made possible by the tremendous efforts of participating sites.

EAQ222CD

This study compares financial navigation and out-of-pocket cost communication versus usual care in patients with solid cancers of any stage. The study similarly reached 92% of its 720-patient accrual goal. Early-stage enrollment, which had been temporarily closed, reopened on May 1, 2026, with strong monthly accrual numbers expected to resume.

EAQ221CD

This study uses a mobile health intervention to improve adherence to CDK4/6 inhibitors in breast cancer patients. As of late April, the study reached over 92% of its accrual goal of 390 participants, with an expected enrollment close by June or July 2026. The study was expanded roughly a year ago to include early-stage patients, broadening its reach and impact.

EAQ241CD, LIFT UP

A rebranding of the FinFit study to "LIFT UP," an acronym for Lessening the Impact of Financial Toxicity. This RCT targets adolescent and young adults (ages 15 to 39) in the post-treatment survivorship phase, combining two evidence-based interventions addressing health insurance literacy at the patient level and financial navigation at the system level. Accrual of 400 participants is planned over 18 months.

MORE CCDR UPDATES

New and Upcoming Studies

Two additional studies are gaining momentum. AYA Access (A232301CD) focuses on improving access to genetic counseling services via an enhanced e-health platform, with 12 patients enrolled thus far, led by Heartland. S2417CD is a pragmatic randomized controlled trial evaluating an intervention to improve guideline adherence for colorectal cancer surveillance, with Metro Minnesota leading early accrual efforts.

Looking Ahead

The NCI is resuming submissions for CCDR concepts and grants. Investigators interested in CCDR-funded projects are encouraged to schedule a presubmission call with CCDR project scientists and research base leadership. Priority will be given to interventional studies, with an emphasis on bridging new discoveries from the NCI and cancer control portfolios into real-world care delivery.

NEW CTSU CRISP NOTIFICATION

CRISP offers two subscription-based notification reports to help sites stay on top of roster and regulatory changes.

1. Regulatory Updates

DTL Task assignments changed to pending or inactive status

This provides a running list of task assignees whose assignments have been system-changed to pending or inactive since the last report. This does not include manually inactivated tasks. Any individual on a participating site roster can subscribe, and users can select one or more sites to monitor. Reports can be delivered daily, weekly, or monthly and include the assignee name, task counts, and affected DTL counts, along with direct links into the DTL application for easy follow-up.

2. Person Roster Updates

Lists all roster members at a user's affiliated sites who currently hold a suspended CTEP status. Any roster member may subscribe and choose one or more rosters to include. Like the first report, delivery is available daily, weekly, or monthly, and each report includes the person's name, suspension date, and associated site and roster information.

Both reports are configurable by site and frequency, making them practical tools for maintaining compliance oversight across your clinical research team.

CLINICAL RESEARCH NEWSLETTER - MAY 2026

Research Base News

WHAT'S NEW WITH SWOG



Expanding the Role of Advanced Practice Providers in Clinical Trials

Advanced Practice Providers (APPs) are playing an increasingly vital role in NCI-sponsored clinical trials. Under updated CTEP and NCORP guidelines, APPs with qualifying credentials can now serve as enrolling investigators, co-chairs, and prescribers of study agent orders when properly credentialed through the NCI Registration and Credential Repository (RCR). Sites are encouraged to roster qualified APPs as NPIVRs and ensure delegation of task logs are updated accordingly to support full APP integration.



OPEN System Modernization: Phase 2 Updates Coming

CTSU is currently in Phase 2 of its OPEN Modernization project, which will bring significant improvements to site-facing screens. Updates will include a redesigned enrollment browser combining in-progress and completed enrollments in one view, improved funding screens, streamlined slot reservation workflows, and enhanced error messaging. The goal is to improve user experience, ensure 508 compliance, and set the stage for future enhancements to cancer clinical trial systems.



New SWOG Study Activations

Several new SWOG studies have recently activated or are planned for activation, expanding options for site participation. These include S2433, a randomized Phase III study of second-line chemotherapy with or without panitumumab for KRAS wild type pancreatic adenocarcinoma, and SN2426, a Phase II study in recurrent metastatic cutaneous squamous cell carcinoma. Sites interested in participating in any of the newly activated Cooperative Treatment Program (CTP) studies are encouraged to reach out to protocols@swogctp.org.



EHR to EDC Integration: nCartes Expansion

SWOG's collaboration with nCartes for electronic health record to electronic data capture integration continues to grow, with 18 sites now in production as of the end of 2025, up from 8 the year prior. Sites using nCartes have reported up to 50% time savings in data entry and notable improvements in data quality. Sites interested in learning more are encouraged to explore the SWOG-nCartes partnership and reach out about joining.

WHAT'S NEW WITH SWOG



Understanding Types of Consent Withdrawal in Clinical Trials

When a patient chooses to withdraw from a clinical trial, it is important for site staff to clearly document exactly what they are withdrawing from. Patients who withdraw from study treatment only are still required to be followed per protocol, while those who withdraw from all future participation and data collection require a formal Consent Withdrawal form to be completed. Proper documentation of the type of withdrawal is essential to maintaining compliance and ensuring appropriate follow-up measures are taken.



Are You FDA Audit Ready?

All studies with the potential for FDA registration also carry the potential for an FDA inspection, making audit readiness an ongoing priority for clinical research sites. Key areas of focus include ensuring the most current IRB-approved consent forms are in use, verifying that source documents support Case Report Form data, maintaining accurate delegation logs, and keeping investigational drug accountability records up to date. Sites can access additional FDA inspection guidance through the Quality Assurance and Audits section of the SWOG FAQs.

SAVE THE DATE:

SWOG QUALITY ASSURANCE WEBINAR

Mark your calendars for the next SWOG Quality Assurance webinar on Tuesday, June 30, 2026, from 11:00 a.m. to 12:00 p.m. CT. The session will cover best practices for investigational drug documentation and management, presented by pharmacists from UC Davis and Indiana University. Participants must enroll in advance through the SWOG ExpertusOne learning management system to attend.

CLINICAL RESEARCH NEWSLETTER

🌻 CORE Fundamentals Training Class 🌻

SIGN UP TODAY - JULY 20-21, 2026

core!

Research Fundamentals TRAINING PROGRAM

CORE Research Fundamentals," a new two-day, in-person training program for cancer clinical research professionals across the state. The program will equip research teams at Georgia's oncology research sites with the knowledge, tools, and confidence to successfully execute cancer clinical trials in real-world settings.



JULY 20-21, 2026
AT 9:00AM - 4:00 PM

THIS CLASS IS VIRTUAL AND A ZOOM LINK WILL BE SENT TO YOU AFTER REGISTRATION IS CLOSED



What You'll Learn:

- Cancer Basics 101
- Clinical Trials 101
- Research Roles & Responsibilities
- Informed Consent Process & Documentation
- Regulatory Compliance
- Eligibility Screening & Enrollment
- Safety Reporting (AEs, SAEs, UPs)
- Protocol Interpretation & Compliance
- Good Documentation Practices

Upon completion of this class, you will need to take the Post test and Evaluation in order to receive CEU Credits!

CLINICAL RESEARCH NEWSLETTER - MAY 2026

🌻 **NCORP News** 🌻

UPCOMING RESEARCH BASE MEETINGS*

Research Base	Date	Location
NRG	July 16-18, 2026	Denver, CO
SWOG	October 8-10, 2026	Chicago, IL
ECOG	October 20 - 22, 2026	Philadelphia, PA
URCC	September 25-27, 2026	Niagara Falls, NY
Wake Forest	October 12-14, 2026	Myrtle Beach, SC
UPCOMING ROUTINE AUDITS ¹		
ECOG	TBD FOR 2026	Exact dates and method (onsite vs virtual) are pending.
NRG	TBD	
SWOG	TBD for 2027	
URCC	TBD for 2027	
Wake Forest	TBD for 2027	

*Please contact Shantoria Brown (sbrown@georgiacore.org) to discuss travel funds and audit preparation.



**ONCOLOGY NURSING COMMITTEE
 NEW CHAIR**
 Stephanie Reyes, replacing
 Bridget O'Brien Fagan
 CONGULATIONS!

**MAY IS MELANOMA AND
 SKIN CANCER DETECTION
 AND PREVENTION MONTH**

Ultraviolet radiation from the sun and tanning beds is the most preventable risk factor for skin cancer, and regular skin checks can significantly improve early detection outcomes.

TRIALS PENDING ACTIVATION

Research Base	Title
ECOG-ACRIN	EAQ241CD: FinFit: Addressing Financial Hardship in AYA Cancer Survivors
	EAQ181: Randomized Controlled Trial of FoRtitude: Targeted eHealth Intervention to Reduce Fear of Recurrence Among Breast Cancer Survivors in Community Oncology Settings
	EAQ161CD: Biomarker Testing in Common Solid Cancers: An Assessment of Current Practices in Precision Oncology in the Community Setting
Alliance	A222302: Family Communications After Genetic Testing
SWOG	S2424CD: Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams

CLINICAL RESEARCH NEWSLETTER - MAY 2026

Trials

RECENTLY ACTIVATED AND RECOMMENDED TRIALS

Research Base	Title	CTSU Activation Date
SWOG	S2419: Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]	4/22/2026
ECOG	EA6232: Phase II Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients with Multiple Atypical Nevi and a Prior History of Melanoma	2/20/2026
	EA1242: A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS	5/20/2026
NRG	NRG-GY035: A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer	1/12/2026
	NRG-CC017: A Randomized Phase III Study Comparing Temporally-Modulated Pulsed Radiation Therapy (TMPRT) Versus Standard Radiation Therapy with Temozolomide for Adults with Newly Diagnosed MGMT-Unmethylated Glioblastoma	4/1/2026
	NRG-HN015: A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS)	1/12/2026
Alliance	A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	1/06/2026
	MMIYA-A04: Phase II Study of Cytarabine + Daunorubicin (7 + 3) + Gemtuzumab Ozogamicin vs. Cytarabine + Daunorubicin (7 + 3) + Venetoclax for the Treatment of Newly Diagnosed Core Binding Factor Acute Myeloid Leukemia (CBF-AML) in Younger Adults: A MyeloMATCH Substudy	5/8/2026
	A082402: Involved-Station, Intensity-Modulated Post-Operative Radiation Therapy (I²-PORT) for Resected Non-Small Cell Lung Cancer with Residual Mediastinal Adenopathy After Neoadjuvant Therapy (ypN2)	5/1/2026
	A212101: Evaluation of Provider vs. Patient Mediated Cascade Genetic Testing of First-Degree Relatives of Patients With Newly Diagnosed Colorectal Cancer	3/5/2026

CLINICAL RESEARCH NEWSLETTER

Trials

OPEN AND ENROLLING CANCER CARE DELIVERY RESEARCH (CCDR) TRIALS

Research Base	Title	CTSU Activation Date
Alliance	A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients	9/26/2025
	A232402CD: PAGODA: Randomized Trial of a Proactive Graduated Dose Modification Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	1/06/2026
ECOG-ACRIN	EAQ221CD: Mobile Health for Adherence in Breast Cancer Patients (CONCURxP) Deemed high priority by the Executive Committee.	10/31/2023
	EAQ222CD: Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) Sites must receive approval prior to initiating any study start-up activities.	2/29/2024
SWOG	S2417CD: A Pragmatic Randomized Controlled Trial To Evaluate The Effectiveness of an Intervention called Current Together After Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance	8/4/2025
Wake Forest	WF-1805CD: Implementation and Effectiveness Trial of HN-STAR Participant enrollment closed as of 2/13/2025, but practice (non-patient) enrollment is now ongoing.	8/10/2020
	WF-2301CD: Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers ² Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.	7/2/2024
	WF-2303CD: Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practice Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.	7/23/2024
	WF-2402CD: Collaborative Oncology between Radiologists and Radiation Oncologists for the Evaluation of Contoured Targets (CORRECT)	2/20/2026
	WF-2502CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	12/02/2025